TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Role of Omega-3 Fish Oil Fatty Acids on Depression Among HIV-seropositive Pregnant Pregnant Women in Nairobi: A Randomized Double-blind Controlled Trial
Brief Summary: Fish oil omega-3 supplements provide essential nutrients for brain health and functioning. These nutrients have been proven to be effective in reducing depressive symptoms. They have also been found to be effective and well tolerated in reducing the bad fat accumulation among patients infected with human immunodeficiency virus (HIV)and are using highly active antiretroviral treatment. The role of this nutritional supplement in combating depression among pregnant women who are living with HIV infection has however not been established. Yet, currently, more than 2 million pregnant women are estimated to be living with HIV infection globally. In Kenya, about 9.0% of pregnant women are HIV-seropositive.

In this study, it is hypothesized that there is no difference in the levels of depressive symptoms among HIV infected pregnant women who are taking omega-3 fish oil supplements and those taking a placebo.

The study will therefore seek to ascertain that taking omega-3 fish oil nutritional supplement has a significant positive effect on depressive symptoms among HIV infected pregnant women, compared to a placebo.


Options:
A: Arm Label: Soybean oil soft gels; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Soybean oil soft gels | Arm Label: Fish oil omega-3 EPA-rich soft gels; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Fish oil omega-3 EPA-rich soft gels | Intervention Type: DIETARY_SUPPLEMENT; Name: Soybean oil soft gels; Assigned to Arm(s): Soybean oil soft gels | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil omega-3 EPA-rich soft gels; Assigned to Arm(s): Fish oil omega-3 EPA-rich soft gels
B: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Drug: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Fish oil concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fish oil concentrate | Arm Label: Placebo oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fish oil concentrate; Assigned to Arm(s): Fish oil concentrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo oil
D: Arm Label: EPA 3.5 g/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega-3 fatty acids | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Omega-3 fatty acids | Arm Label: DHA 1.75 g/day; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 fatty acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 fatty acids; Assigned to Arm(s): DHA 1.75 g/day, EPA 3.5 g/day, Placebo capsules

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: Ataluren; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Part A: 3 to <24 months; Type: EXPERIMENTAL; Interventions: Drug: IVA | Arm Label: Part B + A/B:1 to < 24 months; Type: EXPERIMENTAL; Interventions: Drug: IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part A: 3 to <24 months, Part B + A/B:1 to < 24 months
D: Arm Label: Ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Background: Surveys have shown that antipsychotic drug combinations are frequently prescribed. Amisulpride, an atypical antipsychotic agent, has low incidence of extrapyramidal symptom (EPS) but with high cost compared to sulpiride. The objective of the study is to compare the efficacy and safety of the 800-mg/d amisulpride and 400-mg/d amisulpride plus 800-mg sulpiride in the treatment of acute psychotic exacerbations of schizophrenia.

Method: In this 6-week, double-blind, fixed-dose study, patients with schizophrenia are randomly assigned to amisulpride (800 mg/d) or amisulpride (400 mg/d) plus sulpiride (800 mg/d).The hypothesis is that the two treatment groups have the similar efficacy and safety, but different cost.


Options:
A: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
B: Arm Label: sulpiride plus amisulpride; Type: EXPERIMENTAL; Interventions: Drug: full-dose amisulpride | Arm Label: full-dose amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: full-dose amisulpride | Intervention Type: DRUG; Name: full-dose amisulpride; Assigned to Arm(s): full-dose amisulpride, sulpiride plus amisulpride
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pimozide | Intervention Type: DRUG; Name: Pimozide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
D: Arm Label: A - 10 mg loxapine q 4 h x 3 (30 mg total); Type: EXPERIMENTAL; Interventions: Drug: A - 10 mg loxapine q 4 h x 3 (30 mg total) | Arm Label: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total); Type: EXPERIMENTAL; Interventions: Drug: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total) | Arm Label: C - 5 mg loxapine q 4 h x 3 (15 mg total); Type: EXPERIMENTAL; Interventions: Drug: C - 5 mg loxapine q 4 h x 3 (15 mg total) | Arm Label: D - inhaled placebo q 4 h x 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: D - inhaled placebo q 4 h x 3 | Intervention Type: DRUG; Name: A - 10 mg loxapine q 4 h x 3 (30 mg total); Assigned to Arm(s): A - 10 mg loxapine q 4 h x 3 (30 mg total) | Intervention Type: DRUG; Name: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total); Assigned to Arm(s): B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total) | Intervention Type: DRUG; Name: C - 5 mg loxapine q 4 h x 3 (15 mg total); Assigned to Arm(s): C - 5 mg loxapine q 4 h x 3 (15 mg total) | Intervention Type: DRUG; Name: D - inhaled placebo q 4 h x 3; Assigned to Arm(s): D - inhaled placebo q 4 h x 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Background: Surveys have shown that antipsychotic drug combinations are frequently prescribed. Amisulpride, an atypical antipsychotic agent, has low incidence of extrapyramidal symptom (EPS) but with high cost compared to sulpiride. The objective of the study is to compare the efficacy and safety of the 800-mg/d amisulpride and 400-mg/d amisulpride plus 800-mg sulpiride in the treatment of acute psychotic exacerbations of schizophrenia.

Method: In this 6-week, double-blind, fixed-dose study, patients with schizophrenia are randomly assigned to amisulpride (800 mg/d) or amisulpride (400 mg/d) plus sulpiride (800 mg/d).The hypothesis is that the two treatment groups have the similar efficacy and safety, but different cost.


Options:
A: Arm Label: sulpiride plus amisulpride; Type: EXPERIMENTAL; Interventions: Drug: full-dose amisulpride | Arm Label: full-dose amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: full-dose amisulpride | Intervention Type: DRUG; Name: full-dose amisulpride; Assigned to Arm(s): full-dose amisulpride, sulpiride plus amisulpride
B: Arm Label: Stay on baseline medication prescribed; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Arm Label: Switch per study protocol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Drug: Olanzapine, Drug: Ziprasidone, Drug: Quetiapine, Drug: Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Stay on baseline medication prescribed, Switch per study protocol
C: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Risperidone, long-acting injectable; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Open Label Study Evaluating the Coverage by Teleconsultation Versus Standard Follow-up of Renal Transplant Patients According to a Risk Score of Early Graft Failure (KTFS)
Brief Summary: The main objective of this study is to optimize the coverage of renal transplant patients thanks to a personalized follow-up based on a risk score of early graft failure (KTFS, Kidney Transplant Failure Score), associated with teleconsultations.


Options:
A: Arm Label: Teleconsultation; Type: OTHER; Interventions: Other: Teleconsultation / Standard consultation | Arm Label: Standard consultation; Type: OTHER; Interventions: Other: Teleconsultation / Standard consultation | Intervention Type: OTHER; Name: Teleconsultation / Standard consultation; Assigned to Arm(s): Standard consultation, Teleconsultation
B: Arm Label: Computerised CBT with therapist support; Type: EXPERIMENTAL; Interventions: Behavioral: Computerised Cognitive Behavioural Therapy, Behavioral: Telephone support | Arm Label: Computerised CBT without therapist support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computerised Cognitive Behavioural Therapy | Intervention Type: BEHAVIORAL; Name: Computerised Cognitive Behavioural Therapy; Assigned to Arm(s): Computerised CBT with therapist support, Computerised CBT without therapist support | Intervention Type: BEHAVIORAL; Name: Telephone support; Assigned to Arm(s): Computerised CBT with therapist support
C: Arm Label: Traditional Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: eNephro Application; Type: EXPERIMENTAL; Interventions: Device: Telemedicine System | Intervention Type: DEVICE; Name: Telemedicine System; Assigned to Arm(s): eNephro Application
D: Arm Label: SCT-based behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SCT-based behavioral intervention | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: SCT-based behavioral intervention; Assigned to Arm(s): SCT-based behavioral intervention | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: LIFT: Lifestyle Interventions For Two (Member of the LIFE Moms Consortium)
Brief Summary: This randomized, controlled trial is proposed to study the effect, in a cohort of racially and ethnically diverse group of overweight and obese pregnant women, of an Intensive Lifestyle Intervention (ILI) which utilize cognitive behavioral strategies to help participants achieve and maintain changes in dietary intake and physical activity habits compared to Usual Care (UC) on gestational weight gain (GWG), infant fatness, and mothers' post-delivery weight retention. The hypothesis is that the percent body fat at birth will be significantly less in offspring from ILI mothers than UC mothers.


Options:
A: Arm Label: Enhanced Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced standard care | Arm Label: Intensive lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Enhanced standard care; Assigned to Arm(s): Enhanced Standard Care | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle intervention; Assigned to Arm(s): Intensive lifestyle intervention
B: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Weight Management Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Management | Intervention Type: BEHAVIORAL; Name: Weight Management; Assigned to Arm(s): Weight Management Counseling | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Lifestyle, follow-up, early care, standard care high/low risk; Type: OTHER; Interventions: Behavioral: Lifestyle: diet and exercise | Arm Label: Close follow-up; Type: OTHER; Interventions: Behavioral: Close follow-up: reporting diaries of food and exercise | Intervention Type: BEHAVIORAL; Name: Lifestyle: diet and exercise; Assigned to Arm(s): Lifestyle, follow-up, early care, standard care high/low risk | Intervention Type: BEHAVIORAL; Name: Close follow-up: reporting diaries of food and exercise; Assigned to Arm(s): Close follow-up
D: Arm Label: Intensive Lifestyle Intervention (ILI); Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Lifestyle Intervention (ILI) | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Intervention (ILI); Assigned to Arm(s): Intensive Lifestyle Intervention (ILI) | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women
Brief Summary: This is a double-blind, randomised, placebo-controlled study to assess the safety and efficacy of a silicone elastomer vaginal matrix ring.


Options:
A: Intervention Type: DRUG; Name: 1.0% C31G SAVVY vaginal gel; Assigned to Arm(s): N/A
B: Arm Label: Placebo Vaginal Ring; Type: PLACEBO_COMPARATOR; Interventions: Combination Product: Placebo Vaginal Ring | Arm Label: Dapivirine Vaginal Ring; Type: EXPERIMENTAL; Interventions: Combination Product: Dapivirine Vaginal Ring, 25 mg | Intervention Type: COMBINATION_PRODUCT; Name: Placebo Vaginal Ring; Assigned to Arm(s): Placebo Vaginal Ring | Intervention Type: COMBINATION_PRODUCT; Name: Dapivirine Vaginal Ring, 25 mg; Assigned to Arm(s): Dapivirine Vaginal Ring
C: Arm Label: Tenofovir 1% vaginal gel; Type: EXPERIMENTAL; Interventions: Drug: Tenofovir gel | Arm Label: Universal placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Universal placebo gel | Intervention Type: DRUG; Name: Tenofovir gel; Assigned to Arm(s): Tenofovir 1% vaginal gel | Intervention Type: DRUG; Name: Universal placebo gel; Assigned to Arm(s): Universal placebo gel
D: Arm Label: Dapivirine Vaginal Ring; Type: EXPERIMENTAL; Interventions: Combination Product: Dapivirine Vaginal Ring | Arm Label: Placebo Ring; Type: PLACEBO_COMPARATOR; Interventions: Combination Product: Placebo Ring | Intervention Type: COMBINATION_PRODUCT; Name: Dapivirine Vaginal Ring; Assigned to Arm(s): Dapivirine Vaginal Ring | Intervention Type: COMBINATION_PRODUCT; Name: Placebo Ring; Assigned to Arm(s): Placebo Ring

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hyperimmune Intravenous Immunoglobulin Treatment for Severe H1N1 2009 Infection
Brief Summary: Treatment with hyperimmune intravenous immunoglobulin (H-IVIG), derived from convalescent plasma from patients recovered from H1N1 2009 influenza A infection, for patients with severe H1N1 2009 infection will decrease mortality, reduce viral load, and shorten the length of stay in ICU and hospital.


Options:
A: Arm Label: High-titer anti-influenza plasma; Type: EXPERIMENTAL; Interventions: Biological: High-titer anti-influenza plasma | Arm Label: Low-titer anti-influenza plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Low-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: High-titer anti-influenza plasma; Assigned to Arm(s): High-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: Low-titer anti-influenza plasma; Assigned to Arm(s): Low-titer anti-influenza plasma
B: Arm Label: Plasma and Standard Care; Type: EXPERIMENTAL; Interventions: Biological: Anti-Influenza Immune Plasma, Drug: Standard Care | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Care | Intervention Type: BIOLOGICAL; Name: Anti-Influenza Immune Plasma; Assigned to Arm(s): Plasma and Standard Care | Intervention Type: DRUG; Name: Standard Care; Assigned to Arm(s): Plasma and Standard Care, Standard Care
C: Arm Label: Intravenous immunoglobulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous immunoglobulin | Arm Label: Hyperimmune intravenous immunoglobulin; Type: EXPERIMENTAL; Interventions: Drug: Hyperimmune intravenous immunoglobulin | Intervention Type: DRUG; Name: Hyperimmune intravenous immunoglobulin; Assigned to Arm(s): Hyperimmune intravenous immunoglobulin | Intervention Type: DRUG; Name: Intravenous immunoglobulin; Assigned to Arm(s): Intravenous immunoglobulin
D: Arm Label: Arm A: hIVIG; Type: EXPERIMENTAL; Interventions: Biological: Intravenous hyperimmune immunoglobulin (IVIG) | Arm Label: Arm B: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo for IVIG | Intervention Type: BIOLOGICAL; Name: Intravenous hyperimmune immunoglobulin (IVIG); Assigned to Arm(s): Arm A: hIVIG | Intervention Type: BIOLOGICAL; Name: Placebo for IVIG; Assigned to Arm(s): Arm B: Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hyperimmune Intravenous Immunoglobulin Treatment for Severe H1N1 2009 Infection
Brief Summary: Treatment with hyperimmune intravenous immunoglobulin (H-IVIG), derived from convalescent plasma from patients recovered from H1N1 2009 influenza A infection, for patients with severe H1N1 2009 infection will decrease mortality, reduce viral load, and shorten the length of stay in ICU and hospital.


Options:
A: Arm Label: Convalescent plasma; Type: EXPERIMENTAL; Interventions: Biological: Convalescent plasma | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Convalescent plasma; Assigned to Arm(s): Convalescent plasma
B: Arm Label: Intravenous immunoglobulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous immunoglobulin | Arm Label: Hyperimmune intravenous immunoglobulin; Type: EXPERIMENTAL; Interventions: Drug: Hyperimmune intravenous immunoglobulin | Intervention Type: DRUG; Name: Hyperimmune intravenous immunoglobulin; Assigned to Arm(s): Hyperimmune intravenous immunoglobulin | Intervention Type: DRUG; Name: Intravenous immunoglobulin; Assigned to Arm(s): Intravenous immunoglobulin
C: Arm Label: Convalescent SARS COVID-19 plasma; Type: EXPERIMENTAL; Interventions: Other: Convalescent SARS COVID-19 plasma | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Convalescent SARS COVID-19 plasma; Assigned to Arm(s): Convalescent SARS COVID-19 plasma | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Convalescent plasma; Type: EXPERIMENTAL; Interventions: Biological: Convalescent plasma | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Convalescent plasma; Assigned to Arm(s): Convalescent plasma

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hyperimmune Intravenous Immunoglobulin Treatment for Severe H1N1 2009 Infection
Brief Summary: Treatment with hyperimmune intravenous immunoglobulin (H-IVIG), derived from convalescent plasma from patients recovered from H1N1 2009 influenza A infection, for patients with severe H1N1 2009 infection will decrease mortality, reduce viral load, and shorten the length of stay in ICU and hospital.


Options:
A: Arm Label: Intravenous immunoglobulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous immunoglobulin | Arm Label: Hyperimmune intravenous immunoglobulin; Type: EXPERIMENTAL; Interventions: Drug: Hyperimmune intravenous immunoglobulin | Intervention Type: DRUG; Name: Hyperimmune intravenous immunoglobulin; Assigned to Arm(s): Hyperimmune intravenous immunoglobulin | Intervention Type: DRUG; Name: Intravenous immunoglobulin; Assigned to Arm(s): Intravenous immunoglobulin
B: Intervention Type: BIOLOGICAL; Name: COVID-19 convalescent plasma; Assigned to Arm(s): N/A
C: Arm Label: Plasma and Standard Care; Type: EXPERIMENTAL; Interventions: Biological: Anti-Influenza Immune Plasma, Drug: Standard Care | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Care | Intervention Type: BIOLOGICAL; Name: Anti-Influenza Immune Plasma; Assigned to Arm(s): Plasma and Standard Care | Intervention Type: DRUG; Name: Standard Care; Assigned to Arm(s): Plasma and Standard Care, Standard Care
D: Arm Label: treated; Type: EXPERIMENTAL; Interventions: Other: hyperimmune plasma | Intervention Type: OTHER; Name: hyperimmune plasma; Assigned to Arm(s): treated

Answer: A